PTPN22 and breast carcinoma: An early study showed that LyP-1 could selectively bind to breast cancer cells and induce cell death in vitro, and the proapoptotic activity and the tumor inhibiting effects of LyP-1 were also observed in vivo (Laakkonen et al., 2004).